Wednesday, July 09, 2008 1:51:20 PM
Here are some exerpts
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Wednesday July 9, 8:00 am ET
http://finance.yahoo.com/q?d=t&s=LRP
"TORONTO, July 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced progress made in the Virulizin® development program, including the publication of two research studies on the Virulizin® mode of action and the issuance of a new patent for Virulizin® in Mexico......
Virulizin® has demonstrated significant anticancer activity against a wide range of human cancers in preclinical studies, and has been tested in several clinical trials in solid tumor indications, including a Phase III clinical trial in combination with gemcitabine in locally advanced and metastatic pancreatic cancer. Lorus has reported that the overall survival data in this Phase III study did not reach statistical significance, although exploratory analysis yielded promising results in specific patient populations including in patients with ECOG performance status of 0 or 1."
.....
Virulizin was tried in Mexico with some success against melanoma, but they never finished the effort to get it to market, they were partnered with an Austrailian drug company at the time and the partner could not deal with the Mexican government properly [money talks]. "their culture is incompatible with our standards" is what the Aussie CEO said.
I think LRP can find a way market Viruizin in Europe and Mexico, and it will work quite well and be inexpensive.
Norman
Recent APTO News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 08:15:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:20:21 PM
- Aptose Announces Results from Special Meeting of Shareholders • GlobeNewswire Inc. • 09/05/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 08:35:07 PM
- Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib • GlobeNewswire Inc. • 08/30/2024 08:30:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:35:12 PM
- Aptose Announces Adjournment of its Special Meeting of Shareholders • GlobeNewswire Inc. • 08/15/2024 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:22:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 09:15:13 PM
- Aptose Reports Results for the Second Quarter 2024 • GlobeNewswire Inc. • 08/08/2024 09:06:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 08:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 09:00:14 PM
- Aptose Announces Receipt of Deficiency Notice from Nasdaq • GlobeNewswire Inc. • 07/19/2024 09:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/17/2024 03:43:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:40:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:35:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 02:32:05 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 10:05:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 12:05:15 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/15/2024 03:47:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:06:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 03:35:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:45:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 10:00:16 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM